Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report

被引：1
|
作者：
Ikeo, Satoshi [1 ,2 ,3 ]
Yasuda, Naoaki [1 ]
Sakai, Yuki [1 ]
Hayashi, Yasuyuki [1 ]
Sokai, Akihiko [1 ]
Iwata, Toshiyuki [1 ]
Nishimura, Takashi [1 ]
机构：
[1] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan
[3] Kyoto Katsura Hosp, Dept Resp Med, 17 Yamadahiraocho,Nishikyo Ku, Kyoto 6158256, Japan
来源：
THORACIC CANCER | 2023年 / 14卷 / 10期
基金：
日本学术振兴会;
关键词：
lung cancer; MET exon 14 skipping; tepotinib; transient asymptomatic pulmonary opacities; OSIMERTINIB; AMPLIFICATION; MUTATIONS;
D O I：
10.1111/1759-7714.14831
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET-TKIs) have been approved for the treatment of non-small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (EGFR)-TKIs have been reported. Here, we report a case wherein ground-glass opacities (GGOs) appeared during the course of treatment with tepotinib, a MET-TKI, but spontaneously resolved with drug withdrawal, after which treatment was resumed with a reduced dose. Although there have been no reports of TAPOs with MET-TKIs, the clinical and imaging findings of this case were consistent with TAPOs. For TAPOs occurring because of MET-TKI, the drug can be continued under careful observation even if GGOs appear.
引用
收藏
页码：958 / 960
页数：3
相关论文
共 50 条
  • [31] Immunotherapy for stage IV non-small cell lung cancer patients with MET exon 14 skipping mutation
    Kuon, J.
    Blasi, M.
    Shah, R.
    Christopoulos, P.
    Stenzinger, A.
    Kazdal, D.
    Herth, F. J.
    Heussel, C. P.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 172 - 172
  • [32] Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
    Kraus, Sebastian
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 10
  • [33] Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14
    Kanemura, Hiroaki
    Takeda, Masayuki
    Shimizu, Shigeki
    Nakagawa, Kazuhiko
    THORACIC CANCER, 2021, 12 (04) : 549 - 552
  • [34] Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
    Minne, Rachel L.
    Luo, Natalie Y.
    Traynor, Anne M.
    Huang, Minxuan
    Detullio, Luisina
    Godden, Jen
    Stoppler, Melissa
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [35] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
  • [36] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [37] Molecular cytopathology diagnosis of a lung neoplasm: Case report of an unusual non-small cell carcinoma with MET exon 14 skipping mutation
    Hosseini, S. Mohsen
    Khanafshar, Elham
    Seeley, Eric J.
    Ruiz-Cordero, Roberto
    DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (07) : E258 - E261
  • [38] Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina C.
    Mazieres, Julien
    Viteri, Santiago
    Senellart, Helene
    Van Meerbeeck, Jan
    Raskin, Jo
    Reinmuth, Niels
    Conte, Pierfranco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Patel, Jyoti D.
    Horn, Leora
    Griesinger, Frank
    Han, Ji-Youn
    Kim, Young-Chul
    Chang, Gee-Chen
    Tsai, Chen-Liang
    Yang, James C. -H.
    Chen, Yuh-Min
    Smit, Egbert F.
    van der Wekken, Anthonie J.
    Kato, Terufumi
    Juraeva, Dilafruz
    Stroh, Christopher
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Heymach, John V.
    Le, Xiuning
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10): : 931 - 943
  • [39] Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
    Tseng, Liang-Wei
    Chang, John Wen-Cheng
    Wu, Chiao-En
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [40] Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Hook, Emma S.
    Hatswell, Anthony J.
    Batteson, Rachael L.
    Gaumond, Bruce R.
    O'Brate, Aurora
    Popat, Sanjay
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (08) : 1155 - 1163
12345